Physician Search
Consuelo Wilkins, MD, MSCI, Senior Vice President for Health Equity and Inclusive Excellence for Vanderbilt University Medical Center (VUMC) and Senior Associate Dean for Health Equity and Inclusive Excellence for Vanderbilt University School of Medicine, always knew she wanted to be a physician. "Health equity was built into everything I did, even if I didn’t know it or recognize it at the time," Wilkins said. "I have always learned and believed that people are the same — everyone deserves to be healthy, and everyone should have the best opportunities to take care of themselves and their families." Click below to learn more about health equity initiatives. https://momentum.vicc.org/2021/09/everyone-deserves-to-be-healthy/ |
Vanderbilt was the lead site for an NIH-funded, phase 2, multicenter influenza vaccine study in pediatric allogeneic hematopoietic stem cell transplant (HCT) recipients that may lead to a change in the current flu vaccine recommendations in this vulnerable population. Natasha Halasa, MD, MPH and colleagues recently published in the New England Journal of Medicine, that two doses of high-dose trivalent flu vaccine resulted in higher amounts of influenza-specific antibodies than two doses of standard dose quadrivalent vaccine. https://news.vumc.org/2023/03/02/high-dose-flu-vaccine-beneficial-for-pediatric-stem-cell-transplant-patients/ |
REACH (Research, Education, Advocacy, Clinical Care and Health) for Survivorship Program: Long Term Effects for Survivors of Cancer
Multiple Cancer Types
Miscellaneous,
Pediatrics
N/A
Esbenshade, Adam
VICCPED0710
Infectious Disease Outcomes in Pediatric Oncology Patients
Multiple Cancer Types
Miscellaneous,
Pediatrics
N/A
Esbenshade, Adam
VICCPED14127
Mount Sinai Acute Graft-versus-Host Disease International Consortium (MAGIC): A Database and Biorepository
Miscellaneous
Miscellaneous
Miscellaneous
N/A
Kitko, Carrie
VICCPED1544
Survivorship in Patients Receiving Immune Checkpoint Inhibitors
Miscellaneous
Miscellaneous
Miscellaneous
N/A
Johnson, Douglas
VICCMEL15138
Integrating Comprehensive Precision Tobacco Treatment for Patients with Cancer
Miscellaneous
Miscellaneous
Miscellaneous
N/A
Tindle, Hilary
VICCTHO1886
Patient and Health Care Provider Perspectives of Naloxone
Miscellaneous
Miscellaneous
Miscellaneous
N/A
Hande, Karen
VICCSUPP2068
Pattern of Changes in Immune Profile in the Setting of Chimeric Antigen Receptor T-Cell Therapy
Miscellaneous
Miscellaneous
Miscellaneous
N/A
Oluwole, Olalekan
VICCCTT2074
LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis
Multiple Cancer Types
The LCH-IV is an international, multicenter, prospective clinical study for pediatric
Langerhans Cell Histiocytosis LCH (age < 18 years).
Langerhans Cell Histiocytosis LCH (age < 18 years).
Miscellaneous,
Pediatrics
III
Pastakia, Devang
NCT02205762
VICCPED2231
INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders
Miscellaneous
Miscellaneous
This Phase 1/2, open-label, dose-finding study is intended to evaluate the safety and
tolerability, PK, PD, and efficacy of INCB000928 administered as monotherapy or in
combination with ruxolitinib in participants with MF who are transfusion-dependent or
presenting with symptomatic anemia. This study will consist of 2 parts: dose escalation and
expansion.
tolerability, PK, PD, and efficacy of INCB000928 administered as monotherapy or in
combination with ruxolitinib in participants with MF who are transfusion-dependent or
presenting with symptomatic anemia. This study will consist of 2 parts: dose escalation and
expansion.
Miscellaneous
I/II
Mohan, Sanjay
NCT04455841
VICCHEMP2051